Maintenance therapy comes of age for non-small-cell lung cancer, but at what cost?
- PMID: 21969515
- DOI: 10.1200/JCO.2011.37.8349
Maintenance therapy comes of age for non-small-cell lung cancer, but at what cost?
Comment on
-
Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.J Clin Oncol. 2011 Nov 1;29(31):4113-20. doi: 10.1200/JCO.2010.31.8162. Epub 2011 Oct 3. J Clin Oncol. 2011. PMID: 21969500 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
